Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-02-28 Report Publication Anno…
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
Report Publication Announcement Classification · 98% confidence The document is very short (796 characters) and explicitly states that a 'Finanzbericht' (Financial Report) for the period 01.01.2024 to 31.12.2024 is available on the internet ('Im Internet unter:'). It functions as a notice announcing the publication of a report rather than containing the full report content itself. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the availability of a report should be classified as a Report Publication Announcement (RPA). The filing date of the announcement is 28.02.2025, and the report availability date is 27.03.2025.
2025-02-28 German
Hinweis auf Konzernabschluss vom 01.01.2024 bis zum 31.12.2024
Report Publication Announcement Classification · 98% confidence The document is extremely short (793 characters) and its primary function is to announce where and when a financial report (Konzernabschluss/Consolidated Financial Statements) for the period 01.01.2024 to 31.12.2024 can be accessed online. It explicitly states 'Hinweis auf Konzernabschluss' (Notice of Consolidated Financial Statements) and provides links and dates for publication. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the availability of a full report should be classified as a Report Publication Announcement (RPA). It is not the full report itself (like 10-K or IR).
2025-02-28 German
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea, under the brand name AHZANTIVE
Legal Proceedings Report Classification · 99% confidence The document is a press release dated February 25, 2025, announcing that Formycon AG received regulatory approval in the UK for its biosimilar FYB203 (AHZANTIVE®). The text details the approval by the MHRA, mentions previous approvals by the FDA and European Commission, and discusses commercialization partnerships. This type of announcement, focusing on a specific regulatory milestone (approval) and providing key details about the product and market access, is best classified as a general Regulatory Announcement or News Release. Since there is no specific category for 'Regulatory Approval Announcement' and it is not a full financial report (10-K, IR), earnings release (ER), or a management discussion (MDA), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements that don't fit elsewhere.
2025-02-26 English
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea, under the brand name AHZANTIVE
Regulatory Filings Classification · 100% confidence The document is a press release dated February 25, 2025, announcing that Formycon AG received regulatory approval in the UK for its biosimilar FYB203 (AHZANTIVE®). The text details the approval by the MHRA, mentions previous approvals by the FDA and European Commission, and discusses commercialization partnerships. This type of announcement, focusing on a specific regulatory milestone (approval) and providing key details about the product and market access, is best classified as a general Regulatory Announcement or News Release. Since there is no specific category for 'Regulatory Approval Announcement' and it is not a full financial report (10-K, IR), earnings release (ER), or a management discussion (MDA), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements that don't fit elsewhere.
2025-02-25 English
Formycon AG: Dr. Andreas Seidl, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It details the acquisition of shares by Dr. Andreas Seidl, a Member of the managing body of Formycon AG. This directly matches the definition for Director's Dealing (DIRS). The document length is short, but it is the primary disclosure itself, not an announcement of a separate report.
2025-02-22 English
Formycon AG: Dr. Andreas Seidl, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It details the acquisition of shares by Dr. Andreas Seidl, a Member of the managing body of Formycon AG. This directly matches the definition for Director's Dealing (DIRS). The document length is short, but it is the primary disclosure itself, not an announcement of a separate report.
2025-02-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.